Paratek Pharmaceuticals, Inc., a specialty pharmaceutical company located in King of Prussia, Pennsylvania, will present new findings on NUZYRA® (omadacycline) at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026, scheduled for April 17-21 in Munich, Germany. The presentation will highlight pooled safety data from four Phase 3 clinical trials involving over 1,400 patients suffering from community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Randy Brenner, Chief Development and Regulatory Officer of Paratek, stated that this will be the most comprehensive safety review of NUZYRA to date. Additionally, pivotal data from a study on NUZYRA's efficacy against inhalation anthrax will be presented, supporting future regulatory submissions. The research is backed by federal funding from the Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA). The findings aim to bolster NUZYRA's position in treating serious bacterial infections and highlight its role in addressing public health threats like anthrax.